Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib
Crossref DOI link: https://doi.org/10.1007/s00280-016-3087-6
Published Online: 2016-07-02
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lam, Lisa H.
Capparelli, Edmund V.
Kurzrock, Razelle
License valid from 2016-07-02